Inotek Pharmaceuticals Corporation

Release Summary

Inotek announces Phase 3 development strategy of its lead glaucoma drug, trabodenoson, a first-in-class selective adenosine mimetic designed to restore the eye’s natural pressure control mechanism.

Inotek Pharmaceuticals Corporation